News Year None20202019201820172016201520132012201020092008 July 27, 2020 NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) June 8, 2020 NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D. May 29, 2020 NGM Bio to Present at Two Upcoming Investor Conferences May 27, 2020 NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last » Displaying 5 - 8 of 16
July 27, 2020 NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
